OBJECTIVES: To examine reductions in diarrhea-associated health care utilization after rotavirus vaccine implementation and to assess direct and indirect effectiveness of vaccination. METHODS: Retrospective cohort analysis of claims data of commercially insured US children aged <5 years. We examined annual pentavalent (RV5) and monovalent (RV1) rotavirus vaccine coverage. We compared rates of diarrhea-associated health care utilization in prevaccine (2001-2006) versus postvaccine introduction (2007-2011) years, compared rates of diarrhea-associated health care utilization in vaccinated versus unvaccinated children and compared rates in unvaccinated children in postvaccine versus prevaccine years. RESULTS: Among children aged <5 years, RV5 and RV1 rotavirus vaccine coverage rates reached 58% and 5%, respectively, by December 31, 2010. Compared with the average rate of rotavirus-coded hospitalizations in 2001-2006, rates were reduced by 75% in 2007-2008, 60% in 2008-2009, 94% in 2009-2010, and 80% in 2010-2011. Compared with unvaccinated children, in 2010-2011, the rate of rotavirus-coded hospitalizations was reduced by 92% among RV5 recipients and 96% among RV1 recipients. Rotavirus-coded hospitalization rate reductions among RV5 recipients versus unvaccinated children ranged from 87% among <1-year-olds to 81% among 4-year-olds. Compared with prevaccine rates in 2001-2006, rotavirus-coded hospitalization rates among unvaccinated children decreased by 50% in 2007-2008, 77% in 2009-2010, and 25% in 2010-2011. CONCLUSIONS: Implementation of rotavirus vaccines has substantially reduced diarrhea health care utilization in US children. Both rotavirus vaccines conferred high protection against rotavirus hospitalizations; RV5 conferred durable protection through the fourth year of life. Vaccination also conferred indirect benefits to unvaccinated children.
OBJECTIVES: To examine reductions in diarrhea-associated health care utilization after rotavirus vaccine implementation and to assess direct and indirect effectiveness of vaccination. METHODS: Retrospective cohort analysis of claims data of commercially insured US children aged <5 years. We examined annual pentavalent (RV5) and monovalent (RV1) rotavirus vaccine coverage. We compared rates of diarrhea-associated health care utilization in prevaccine (2001-2006) versus postvaccine introduction (2007-2011) years, compared rates of diarrhea-associated health care utilization in vaccinated versus unvaccinated children and compared rates in unvaccinated children in postvaccine versus prevaccine years. RESULTS: Among children aged <5 years, RV5 and RV1 rotavirus vaccine coverage rates reached 58% and 5%, respectively, by December 31, 2010. Compared with the average rate of rotavirus-coded hospitalizations in 2001-2006, rates were reduced by 75% in 2007-2008, 60% in 2008-2009, 94% in 2009-2010, and 80% in 2010-2011. Compared with unvaccinated children, in 2010-2011, the rate of rotavirus-coded hospitalizations was reduced by 92% among RV5 recipients and 96% among RV1 recipients. Rotavirus-coded hospitalization rate reductions among RV5 recipients versus unvaccinated children ranged from 87% among <1-year-olds to 81% among 4-year-olds. Compared with prevaccine rates in 2001-2006, rotavirus-coded hospitalization rates among unvaccinated children decreased by 50% in 2007-2008, 77% in 2009-2010, and 25% in 2010-2011. CONCLUSIONS: Implementation of rotavirus vaccines has substantially reduced diarrhea health care utilization in US children. Both rotavirus vaccines conferred high protection against rotavirus hospitalizations; RV5 conferred durable protection through the fourth year of life. Vaccination also conferred indirect benefits to unvaccinated children.
Authors: Jacqueline E Tate; Jeffry D Mutuc; Catherine A Panozzo; Daniel C Payne; Margaret M Cortese; Jennifer E Cortes; Catherine Yen; Douglas H Esposito; Benjamin A Lopman; Manish M Patel; Umesh D Parashar Journal: Pediatr Infect Dis J Date: 2011-01 Impact factor: 2.129
Authors: Mark A Malek; Aaron T Curns; Robert C Holman; Thea K Fischer; Joseph S Bresee; Roger I Glass; Claudia A Steiner; Umesh D Parashar Journal: Pediatrics Date: 2006-06 Impact factor: 7.124
Authors: Jennifer E Cortes; Aaron T Curns; Jacqueline E Tate; Margaret M Cortese; Manish M Patel; Fangjun Zhou; Umesh D Parashar Journal: N Engl J Med Date: 2011-09-22 Impact factor: 91.245
Authors: Daniel C Payne; Mary Allen Staat; Kathryn M Edwards; Peter G Szilagyi; Jon R Gentsch; Lauren J Stockman; Aaron T Curns; Marie Griffin; Geoffrey A Weinberg; Caroline B Hall; Gerry Fairbrother; James Alexander; Umesh D Parashar Journal: Pediatrics Date: 2008-12 Impact factor: 7.124
Authors: Scott P Grytdal; Dana L Haberling; Jordan L Kennedy; Jeffrey T McCollum; Umesh D Parashar Journal: J Pediatric Infect Dis Soc Date: 2018-05-15 Impact factor: 3.164
Authors: Andrej Steyer; Monika Jevšnik; Miroslav Petrovec; Marko Pokorn; Štefan Grosek; Adela Fratnik Steyer; Barbara Šoba; Tina Uršič; Tjaša Cerar Kišek; Marko Kolenc; Marija Trkov; Petra Šparl; Raja Duraisamy; W Ian Lipkin; Sara Terzić; Mojca Kolnik; Tatjana Mrvič; Amit Kapoor; Franc Strle Journal: Pediatr Infect Dis J Date: 2016-09 Impact factor: 2.129
Authors: Aleisha M Nabower; Matt Hall; Jason Burrows; Amanda Dave; Ashley Deschamp; Chinenye R Dike; Joshua C Euteneuer; Teri Mauch; Russell McCulloh; Laura Ortmann; Kari Simonsen; Gwenn Skar; Jessica Snowden; Veronica Taylor; Jessica L Markham Journal: Hosp Pediatr Date: 2020-06-03
Authors: John Coveney; Michael Barrett; Patrick Fitzpatrick; Nandini Kandamany; Roisin Mcnamara; Stanley Koe; Ikechukwu Okafor Journal: Ir J Med Sci Date: 2019-06-13 Impact factor: 1.568
Authors: Sue E Crawford; Sasirekha Ramani; Jacqueline E Tate; Umesh D Parashar; Lennart Svensson; Marie Hagbom; Manuel A Franco; Harry B Greenberg; Miguel O'Ryan; Gagandeep Kang; Ulrich Desselberger; Mary K Estes Journal: Nat Rev Dis Primers Date: 2017-11-09 Impact factor: 52.329